A Phase 2 interventional study of Placebo and PF-06651600 in Rheumatoid Arthritis, sponsored by Pfizer. Completed at 30 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-12-04.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 152 studies in Arthritis, Rheumatoid by Pfizer — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Pfizer.
Among the 152 studies in Arthritis, Rheumatoid by Pfizer, this one is the 59th largest by enrollment of the 86 interventional ones that give a count, is one of 5 that started in 2016, is one of 28 in phase 2, and was the 124th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 152 studies in Arthritis, Rheumatoid by Pfizer are open now, in 1 country. Recruiting first, the newest first:
Pfizer · Sites in Korea, Republic of
Ages 18+
Pfizer
Ages 18–70
By country, each count listing its studies:
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
152 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 29 · Phase 3 18 · Phase 4 17
First in 2003; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 155 across the 86 interventional studies, 421 across the 63 observational. Of the 149 that completed or were terminated, 105 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 152 studies in Arthritis, Rheumatoid by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an 8 week study to assess the efficacy and safety profile of PF-06651600 in seropositive subjects with rheumatoid arthritis with an inadequate response to methotrexate (up to approximately 50% of subjects may also have had an inadequate response to 1 anti-TNF biologic).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Study Drug
Drug: PF-06651600
Placebo
Drug: Placebo
200mg pill every day (QD) for 8 weeks
Change From Baseline in Simple Disease Activity Index (SDAI) Score at Week 8
The SDAI is the numerical sum of five outcome parameters: tender joint count (TJC) and swollen joint count (SJC) based on a 28-joint assessment, patient global assessment (PtGA) and physician global assessment (PGA) assessed on a visual analogue scale (VAS) scale ranging from 0 to 10 centimeter (cm), where higher scores=greater affection due to disease activity, and C-reactive protein (CRP) measured in terms of milligram per deciliter (mg/dL). SDAI total score= 0 to 86. SDAI greater than or equal to (\<=) 3.3 indicates disease remission, greater than (\>) 3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high disease activity.
Time frame: Baseline, Week 8
Number of Participants With Vital Signs Abnormalities
Criteria: sitting pulse rate less than (\<) 40 beats per minute (bpm) or \>120 bpm; sitting systolic blood pressure (SBP) \>=30 millimeters of mercury (mmHg) change from baseline in same posture or \<90 mmHg; diastolic blood pressure (DBP) \>=20 mmHg change from baseline in same posture or \<50 mmHg. Only those categories in which at least one participant had abnormality, were reported in this outcome measure.
Time frame: Baseline up to Week 12
Number of Participants With Laboratory Abnormalities
Hemoglobin(Hb);hematocrit;RBC count:\<0.8\*lower limit of normal (LLN),mean corpuscular volume;mean corpuscular Hb concentration:\<0.9\*LLN or\>1.1\*upper limit of normal (ULN), platelet:\<0.5\*LLN or \>1.75\*ULN,reticulocytes \<0.5\*LLN or \>1.5\*ULN,leukocytes \<0.6\*LLN or \>1.5\*ULN,lymphocyte;neutrophil: \<0.8\*LLN or \>1.2\*ULN,basophil;eosinophil; monocyte:\>1.2\*ULN,partial thromboplastin time,prothrombin time\>1.1\*ULN,bilirubin\>1.5\*ULN, aspartate aminotransferase; alanine aminotransferase;alkaline phosphatase:\>3.0\*ULN,protein;albumin;LDL, HDL cholesterol:\<0.8\*LLN or \>1.2\*ULN;urea nitrogen;creatinine: \>1.3\*ULN, urate \>1.2\*ULN, sodium\<0.95\*LLN or \>1.05\*ULN, potassium; chloride;calcium; bicarbonate:\<0.9\*LLN or \>1.1\*ULN,glucose \<0.6\*LLN or \>1.5\*ULN, creatine kinase: \>2.0\*ULN;urine pH \<4.5 or \>8,urine glucose or ketones\>=1,urine protein;urineHb\>=1,urobilinogen;bilirubin;nitrite;leukocyte esterase \>=1,urine erythrocytes, leukocytes\>=20,hyaline cast\>1,bacteria\>20.
Time frame: Baseline up to Week 12
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Week 12 that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Baseline up to Week 12
Change From Baseline in Simple Disease Activity Index (SDAI) Score at Week 1, 2, 4 and 6
The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and PGA assessed on a VAS scale ranging from 0 to 10 cm, where higher scores=greater affection due to disease activity, and CRP measured in terms of mg/dL. SDAI total score= 0 to 86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high disease activity.
Time frame: Baseline, Week 1, 2, 4 and 6
Remission Rate Based on Simple Disease Activity Index Score
Remission rate was defined as percentage of participants with disease remission. The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and PGA assessed on a VAS scale ranging from 0 to 10 cm, where higher scores=greater affection due to disease activity, and CRP measured in terms of mg/dL. SDAI total score= 0 to 86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high disease activity.
Time frame: Week 4, 6 and 8
Remission Rate Based on Disease Activity Score (DAS28-3 [ESR])
Remission rate was defined as the percentage of participants with disease remission. DAS28 is measure of disease activity in participants with rheumatoid arthritis. DAS28-3 (ESR) was calculated from SJC and TJC using 28 joints count, and erythrocyte sedimentation rate (ESR) (millimeters per hour \[mm/hr\]). Total score range: 0-9.4, higher score=more disease activity. DAS28-3 (ESR) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (ESR) \<2.6 = remission.
Time frame: Week 4, 6 and 8
Remission Rate Based on Disease Activity Score (DAS28-4[ESR])
Remission rate was defined as the percentage of participants with disease remission. DAS28 is measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from the number of SJC and TJC using the 28 joints count, the ESR (mm/hour) and participant's global assessment (PGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). Total score range: 0-9.4, higher score=more disease activity. DAS28-4 (ESR) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-4 (ESR) \<2.6 = remission.
Time frame: Week 4, 6 and 8
Remission Rate Based on Disease Activity Score (DAS28-3 [CRP])
Remission rate was defined as the percentage of participants with disease remission. DAS28 is measure of disease activity in participants with rheumatoid arthritis. DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \<2.6 = remission.
Time frame: Week 4, 6 and 8
Remission Rate Based on Disease Activity Score (DAS28-4 [CRP])
Remission rate was defined as the percentage of participants with disease remission. DAS28 is measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (CRP): calculated from SJC, TJC, CRP (mg/L) and PGA (participant rated disease activity on VAS from 0 to 100 mm; high score=worse health). Total score range of DAS28-4 (CRP): 0 to 9.4(0=no activity; 9.4=extreme disease activity), higher score=more disease activity. DAS28-4(CRP) \<2.6=remission, \<3.2=low disease activity, \>=3.2-5.1=moderate disease activity and \>5.1=high disease activity.
Time frame: Week 4, 6 and 8
Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 [ESR]) at Week 1, 2, 4, 6 and 8
DAS28 is measure of disease activity in participants with rheumatoid arthritis. DAS28-3 (ESR) was calculated from SJC and TJC using 28 joints count, and ESR (mm/hr). Total score range: 0-9.4, higher score=more disease activity. DAS28-3 (ESR) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (ESR) \<2.6 = remission.
Time frame: Baseline, Week 1, 2, 4, 6 and 8
Change From Baseline in Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Week 1, 2, 4, 6 and 8
DAS28 is measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hr) and PtGA of disease activity (participant rated arthritis activity assessment). Total score range: 0-9.4, higher score=more disease activity. DAS28-4 (ESR) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-4 (ESR) \<2.6 = remission.
Time frame: Baseline, Week 1, 2, 4, 6 and 8
Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 1, 2, 4, 6 and 8
DAS28 is measure of disease activity in participants. DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \<2.6 = remission.
Time frame: Baseline, Week 1, 2, 4, 6 and 8
Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP]) at Week 1, 2, 4, 6 and 8
DAS28 is measure of disease activity in participants. DAS28-4 (CRP): calculated from SJC, TJC, CRP(mg/L) and PGA (participant rated disease activity on VAS from 0 to 100 mm; high score=worse health). Total score range of DAS28-4 (CRP): 0 to 9.4(0=no activity; 9.4=extreme disease activity), higher score=more disease activity. DAS28-4(CRP) \<2.6=remission, \<3.2=low disease activity, \>=3.2-5.1=moderate disease activity and \>5.1=high disease activity.
Time frame: Baseline, Week 1, 2, 4, 6 and 8
Change From Baseline in High Sensitivity C-Reactive Protein (hsCRP) Concentration at Week 1, 2, 4, 6 and 8
Time frame: Baseline, Week 1, 2, 4, 6 and 8
Change From Baseline in the Tender Joint Count and Swollen Joint Count at Week 1, 2, 4, 6 and 8
Tender joint count was an assessment of 68 joints (upper body, upper extremity, and lower extremity). Each joint's response to pressure/motion was assessed as: Present or Absent. Swollen joint count was an assessment of 66 joints (upper body, upper extremity, and lower extremity). Each joint was assessed for swelling as: Present or Absent.
Time frame: Baseline, Week 1, 2, 4, 6 and 8
Change From Baseline in Participant's Assessment of Arthritis Pain (PAAP), Participant's Global Assessment of Arthritis (PGA) and Physician's Global Assessment of Arthritis (PGAA) at Week 1, 2, 4, 6 and 8
PAAP: Participants assessed the severity of their arthritis pain by using a 100 mm VAS ranging from 0 (no pain) to 100 (most severe pain), which corresponded to the magnitude of their pain, where higher scores indicated more pain. PGA: Participants were asked the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" and their response was recorded on a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated worse health condition. PGAA: Participants were assessed how their overall arthritis appears at the time of the visit. The evaluation was based on the participant's disease signs, functional capacity and physical examination, and was independent of the PAAP and PGA assessments. The physician's response was recorded using a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated more disease activity.
Time frame: Baseline, Week 1, 2, 4, 6 and 8
Change From Baseline in Health Assessment Questionnaire-Disability Index [HAQ-DI] at Week 1, 2, 4, 6 and 8
HAQ-DI assess degree of difficulty a participant experienced (during past week) in 8 domain of daily activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip and other activities. Each item scored on a 4-point scale ranging from 0 to 3(0=no difficulty; 3=extreme difficulty). Overall score: average of the sum of domain scores/number of domains answered. Total possible score range (0=least difficulty; 3=extreme difficulty); high scores=more difficulty in performing daily living activities.
Time frame: Baseline, Week 1, 2, 4, 6 and 8
| Milestone | PF-06651600 | Placebo |
|---|---|---|
| Started | 42 | 28 |
| Completed | 37 | 22 |
| Not completed | 5 | 6 |
| Withdrew: Withdrawal by subject | 2 | 6 |
| Withdrew: Adverse event | 3 | 0 |
The SDAI is the numerical sum of five outcome parameters: tender joint count (TJC) and swollen joint count (SJC) based on a 28-joint assessment, patient global assessment (PtGA) and physician global assessment (PGA) assessed on a visual analogue scale (VAS) scale ranging from 0 to 10 centimeter (cm), where higher scores=greater affection due to disease activity, and C-reactive protein (CRP) measured in terms of milligram per deciliter (mg/dL). SDAI total score= 0 to 86. SDAI greater than or equal to (\<=) 3.3 indicates disease remission, greater than (\>) 3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high disease activity.
| units on a scale | PF-06651600 | Placebo |
|---|---|---|
| Baseline | 45.15 ± 13.164 | 44.85 ± 13.976 |
| Change at Week 8 | -26.11 ± 14.834 | -17.38 ± 18.176 |
Criteria: sitting pulse rate less than (\<) 40 beats per minute (bpm) or \>120 bpm; sitting systolic blood pressure (SBP) \>=30 millimeters of mercury (mmHg) change from baseline in same posture or \<90 mmHg; diastolic blood pressure (DBP) \>=20 mmHg change from baseline in same posture or \<50 mmHg. Only those categories in which at least one participant had abnormality, were reported in this outcome measure.
| Participants | PF-06651600 | Placebo |
|---|---|---|
| Sitting DBP >=20 mmHg increase from baseline | 3 | 0 |
| Sitting DBP >=20 mmHg decrease from baseline | 0 | 1 |
Hemoglobin(Hb);hematocrit;RBC count:\<0.8\*lower limit of normal (LLN),mean corpuscular volume;mean corpuscular Hb concentration:\<0.9\*LLN or\>1.1\*upper limit of normal (ULN), platelet:\<0.5\*LLN or \>1.75\*ULN,reticulocytes \<0.5\*LLN or \>1.5\*ULN,leukocytes \<0.6\*LLN or \>1.5\*ULN,lymphocyte;neutrophil: \<0.8\*LLN or \>1.2\*ULN,basophil;eosinophil; monocyte:\>1.2\*ULN,partial thromboplastin time,prothrombin time\>1.1\*ULN,bilirubin\>1.5\*ULN, aspartate aminotransferase; alanine aminotransferase;alkaline phosphatase:\>3.0\*ULN,protein;albumin;LDL, HDL cholesterol:\<0.8\*LLN or \>1.2\*ULN;urea nitrogen;creatinine: \>1.3\*ULN, urate \>1.2\*ULN, sodium\<0.95\*LLN or \>1.05\*ULN, potassium; chloride;calcium; bicarbonate:\<0.9\*LLN or \>1.1\*ULN,glucose \<0.6\*LLN or \>1.5\*ULN, creatine kinase: \>2.0\*ULN;urine pH \<4.5 or \>8,urine glucose or ketones\>=1,urine protein;urineHb\>=1,urobilinogen;bilirubin;nitrite;leukocyte esterase \>=1,urine erythrocytes, leukocytes\>=20,hyaline cast\>1,bacteria\>20.
| Participants | PF-06651600 | Placebo |
|---|---|---|
| Number of Participants With Laboratory Abnormalities | 42 | 28 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Week 12 that were absent before treatment or that worsened relative to pretreatment state.
| Participants | PF-06651600 | Placebo |
|---|---|---|
| AEs | 20 | 5 |
| SAEs | 0 | 0 |
The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and PGA assessed on a VAS scale ranging from 0 to 10 cm, where higher scores=greater affection due to disease activity, and CRP measured in terms of mg/dL. SDAI total score= 0 to 86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high disease activity.
| units on a scale | PF-06651600 | Placebo |
|---|---|---|
| Change at Week 1 | -4.59 ± 9.409 | -4.52 ± 7.025 |
| Change at Week 2 | -12.82 ± 10.969 | -8.05 ± 9.402 |
| Change at Week 4 | -17.79 ± 12.804 | -12.55 ± 13.462 |
| Change at Week 6 | -22.79 ± 14.007 | -15.62 ± 14.231 |
Remission rate was defined as percentage of participants with disease remission. The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and PGA assessed on a VAS scale ranging from 0 to 10 cm, where higher scores=greater affection due to disease activity, and CRP measured in terms of mg/dL. SDAI total score= 0 to 86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high disease activity.
| percentage of participants | PF-06651600 | Placebo |
|---|---|---|
| Week 4 | 4.8 | 0.0 |
| Week 6 | 4.8 | 0.0 |
| Week 8 | 7.1 | 0.0 |
Remission rate was defined as the percentage of participants with disease remission. DAS28 is measure of disease activity in participants with rheumatoid arthritis. DAS28-3 (ESR) was calculated from SJC and TJC using 28 joints count, and erythrocyte sedimentation rate (ESR) (millimeters per hour \[mm/hr\]). Total score range: 0-9.4, higher score=more disease activity. DAS28-3 (ESR) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (ESR) \<2.6 = remission.
| percentage of participants | PF-06651600 | Placebo |
|---|---|---|
| Week 4 | 4.8 | 0.0 |
| Week 6 | 2.4 | 0.0 |
| Week 8 | 7.1 | 0.0 |
Remission rate was defined as the percentage of participants with disease remission. DAS28 is measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from the number of SJC and TJC using the 28 joints count, the ESR (mm/hour) and participant's global assessment (PGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). Total score range: 0-9.4, higher score=more disease activity. DAS28-4 (ESR) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-4 (ESR) \<2.6 = remission.
| percentage of participants | PF-06651600 | Placebo |
|---|---|---|
| Week 4 | 4.8 | 0.0 |
| Week 6 | 4.8 | 0.0 |
| Week 8 | 7.1 | 0.0 |
Remission rate was defined as the percentage of participants with disease remission. DAS28 is measure of disease activity in participants with rheumatoid arthritis. DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \<2.6 = remission.
| percentage of participants | PF-06651600 | Placebo |
|---|---|---|
| Week 4 | 9.5 | 0.0 |
| Week 6 | 7.1 | 3.6 |
| Week 8 | 9.5 | 0.0 |
Remission rate was defined as the percentage of participants with disease remission. DAS28 is measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (CRP): calculated from SJC, TJC, CRP (mg/L) and PGA (participant rated disease activity on VAS from 0 to 100 mm; high score=worse health). Total score range of DAS28-4 (CRP): 0 to 9.4(0=no activity; 9.4=extreme disease activity), higher score=more disease activity. DAS28-4(CRP) \<2.6=remission, \<3.2=low disease activity, \>=3.2-5.1=moderate disease activity and \>5.1=high disease activity.
| percentage of participants | PF-06651600 | Placebo |
|---|---|---|
| Week 4 | 9.5 | 0.0 |
| Week 6 | 9.5 | 3.6 |
| Week 8 | 9.5 | 0.0 |
DAS28 is measure of disease activity in participants with rheumatoid arthritis. DAS28-3 (ESR) was calculated from SJC and TJC using 28 joints count, and ESR (mm/hr). Total score range: 0-9.4, higher score=more disease activity. DAS28-3 (ESR) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (ESR) \<2.6 = remission.
| units on a scale | PF-06651600 | Placebo |
|---|---|---|
| Baseline | 6.49 ± 0.762 | 6.37 ± 0.815 |
| Change at Week 1 | -0.19 ± 0.604 | -0.26 ± 0.434 |
| Change at Week 2 | -0.67 ± 0.602 | -0.46 ± 0.531 |
| Change at Week 4 | -1.16 ± 1.125 | -0.78 ± 0.905 |
| Change at Week 6 | -1.54 ± 1.123 | -1.07 ± 0.989 |
| Change at Week 8 | -1.85 ± 1.161 | -1.07 ± 1.214 |
DAS28 is measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hr) and PtGA of disease activity (participant rated arthritis activity assessment). Total score range: 0-9.4, higher score=more disease activity. DAS28-4 (ESR) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-4 (ESR) \<2.6 = remission.
| units on a scale | PF-06651600 | Placebo |
|---|---|---|
| Baseline | 6.82 ± 0.815 | 6.72 ± 0.880 |
| Change at Week 1 | -0.27 ± 0.553 | -0.27 ± 0.477 |
| Change at Week 2 | -0.83 ± 0.695 | -0.47 ± 0.551 |
| Change at Week 4 | -1.36 ± 1.173 | -0.89 ± 0.951 |
| Change at Week 6 | -1.81 ± 1.179 | -1.18 ± 1.050 |
| Change at Week 8 | -2.14 ± 1.269 | -1.22 ± 1.448 |
DAS28 is measure of disease activity in participants. DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) \<= 3.2 implied low disease activity and \>3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) \<2.6 = remission.
| units on a scale | PF-06651600 | Placebo |
|---|---|---|
| Baseline | 5.76 ± 0.824 | 5.61 ± 0.894 |
| Change at Week 1 | -0.35 ± 0.741 | -0.20 ± 0.456 |
| Change at Week 2 | -0.86 ± 0.782 | -0.47 ± 0.585 |
| Change at Week 4 | -1.33 ± 1.219 | -0.72 ± 1.005 |
| Change at Week 6 | -1.53 ± 1.286 | -1.01 ± 0.993 |
| Change at Week 8 | -1.79 ± 1.265 | -1.03 ± 1.146 |
DAS28 is measure of disease activity in participants. DAS28-4 (CRP): calculated from SJC, TJC, CRP(mg/L) and PGA (participant rated disease activity on VAS from 0 to 100 mm; high score=worse health). Total score range of DAS28-4 (CRP): 0 to 9.4(0=no activity; 9.4=extreme disease activity), higher score=more disease activity. DAS28-4(CRP) \<2.6=remission, \<3.2=low disease activity, \>=3.2-5.1=moderate disease activity and \>5.1=high disease activity.
| units on a scale | PF-06651600 | Placebo |
|---|---|---|
| Baseline | 6.11 ± 0.850 | 5.98 ± 0.926 |
| Change at Week 1 | -0.41 ± 0.685 | -0.21 ± 0.473 |
| Change at Week 2 | -0.99 ± 0.823 | -0.47 ± 0.574 |
| Change at Week 4 | -1.49 ± 1.222 | -0.82 ± 1.013 |
| Change at Week 6 | -1.78 ± 1.304 | -1.09 ± 1.057 |
| Change at Week 8 | -2.06 ± 1.321 | -1.16 ± 1.367 |
| milligram per deciliter | PF-06651600 | Placebo |
|---|---|---|
| Baseline | 2.00 ± 1.816 | 1.68 ± 2.853 |
| Change at Week 1 | -0.20 ± 2.672 | 0.60 ± 2.263 |
| Change at Week 2 | -0.62 ± 2.090 | -0.04 ± 0.966 |
| Change at Week 4 | -0.93 ± 1.591 | 0.00 ± 1.335 |
| Change at Week 6 | -0.42 ± 2.376 | -0.23 ± 1.327 |
| Change at Week 8 | -0.89 ± 2.142 | -0.04 ± 2.220 |
Tender joint count was an assessment of 68 joints (upper body, upper extremity, and lower extremity). Each joint's response to pressure/motion was assessed as: Present or Absent. Swollen joint count was an assessment of 66 joints (upper body, upper extremity, and lower extremity). Each joint was assessed for swelling as: Present or Absent.
| joint count | PF-06651600 | Placebo |
|---|---|---|
| Baseline: Tender joint count | 16.74 ± 6.765 | 16.75 ± 6.681 |
| Baseline: Swollen joint count | 12.95 ± 5.396 | 12.11 ± 6.160 |
| Change at Week 1: Tender joint count | -1.54 ± 4.915 | -1.96 ± 2.701 |
| Change at Week 1: Swollen joint count | -1.49 ± 4.439 | -2.46 ± 3.501 |
| Change at Week 2: Tender joint count | -4.40 ± 5.522 | -2.56 ± 5.213 |
| Change at Week 2: Swollen joint count | -4.71 ± 4.430 | -4.11 ± 4.619 |
| Change at Week 4: Tender joint count | -6.76 ± 6.818 | -4.96 ± 7.750 |
| Change at Week 4: Swollen joint count | -5.95 ± 4.950 | -4.85 ± 4.961 |
| Change at Week 6: Tender joint count | -8.75 ± 7.132 | -6.42 ± 6.652 |
| Change at Week 6: Swollen joint count | -7.80 ± 5.743 | -5.85 ± 5.540 |
| Change at Week 8: Tender joint count | -10.21 ± 7.259 | -6.83 ± 7.755 |
| Change at Week 8: Swollen joint count | -8.59 ± 6.176 | -6.54 ± 6.324 |
PAAP: Participants assessed the severity of their arthritis pain by using a 100 mm VAS ranging from 0 (no pain) to 100 (most severe pain), which corresponded to the magnitude of their pain, where higher scores indicated more pain. PGA: Participants were asked the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" and their response was recorded on a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated worse health condition. PGAA: Participants were assessed how their overall arthritis appears at the time of the visit. The evaluation was based on the participant's disease signs, functional capacity and physical examination, and was independent of the PAAP and PGA assessments. The physician's response was recorded using a 100 mm VAS ranging from 0 (very well) to 100 (very poor), where higher scores indicated more disease activity.
| units on a scale | PF-06651600 | Placebo |
|---|---|---|
| Baseline: PAAP | 66.64 ± 16.771 | 71.75 ± 16.183 |
| Baseline: PGA | 68.43 ± 15.639 | 69.00 ± 16.115 |
| Baseline: PGAA | 66.17 ± 14.228 | 74.07 ± 12.844 |
| Change at Week 1: PAAP | -4.95 ± 11.388 | -2.86 ± 14.847 |
| Change at Week 1: PGA | -6.76 ± 11.128 | -1.93 ± 9.149 |
| Change at Week 1: PGAA | -6.83 ± 8.947 | -4.96 ± 8.126 |
| Change at Week 2: PAAP | -11.90 ± 18.061 | -6.04 ± 12.669 |
| Change at Week 2: PGA | -14.74 ± 15.963 | -2.81 ± 9.931 |
| Change at Week 2: PGAA | -16.07 ± 16.499 | -10.63 ± 12.500 |
| Change at Week 4: PAAP | -19.88 ± 16.695 | -10.23 ± 25.513 |
| Change at Week 4: PGA | -20.05 ± 13.746 | -12.12 ± 19.574 |
| Change at Week 4: PGAA | -21.49 ± 16.715 | -17.96 ± 18.877 |
| Change at Week 6: PAAP | -27.90 ± 20.061 | -12.35 ± 27.425 |
| Change at Week 6: PGA | -27.83 ± 18.936 | -11.65 ± 21.630 |
| Change at Week 6: PGAA | -30.45 ± 17.868 | -19.50 ± 22.963 |
| Change at Week 8: PAAP | -32.92 ± 25.051 | -18.58 ± 34.152 |
| Change at Week 8: PGA | -30.92 ± 21.279 | -15.88 ± 30.135 |
| Change at Week 8: PGAA | -33.28 ± 18.725 | -23.75 ± 25.902 |
HAQ-DI assess degree of difficulty a participant experienced (during past week) in 8 domain of daily activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip and other activities. Each item scored on a 4-point scale ranging from 0 to 3(0=no difficulty; 3=extreme difficulty). Overall score: average of the sum of domain scores/number of domains answered. Total possible score range (0=least difficulty; 3=extreme difficulty); high scores=more difficulty in performing daily living activities.
| units on a scale | PF-06651600 | Placebo |
|---|---|---|
| Baseline | 1.79 ± 0.577 | 1.69 ± 0.550 |
| Change at Week 1 | -0.13 ± 0.391 | -0.04 ± 0.316 |
| Change at Week 2 | -0.26 ± 0.430 | -0.15 ± 0.347 |
| Change at Week 4 | -0.39 ± 0.414 | -0.19 ± 0.534 |
| Change at Week 6 | -0.46 ± 0.527 | -0.23 ± 0.609 |
| Change at Week 8 | -0.53 ± 0.583 | -0.32 ± 0.671 |
Collected over Baseline up to Week 12. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-06651600 | 0/42 (0%) | 0/42 (0%) | 20/42 (47.6%) |
| Placebo | 0/28 (0%) | 0/28 (0%) | 5/28 (17.9%) |
| Event | PF-06651600 | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 0/42 | 3/28 |
| LymphopeniaBlood and lymphatic system disorders | 3/42 | 0/28 |
| InfluenzaInfections and infestations | 3/42 | 0/28 |
| PruritusSkin and subcutaneous tissue disorders | 2/42 | 1/28 |
| Upper respiratory tract infectionInfections and infestations | 0/42 | 1/28 |
| Alanine aminotransferase increasedInvestigations | 0/42 | 1/28 |
| Aspartate aminotransferase increasedInvestigations | 0/42 | 1/28 |
| Spinal painMusculoskeletal and connective tissue disorders | 0/42 | 1/28 |
| Abdominal distensionGastrointestinal disorders | 1/42 | 0/28 |
| GlossitisGastrointestinal disorders | 1/42 | 0/28 |
Intent to treat (ITT) analysis set included all participants who were randomized to the study and received at least one dose of the randomized investigational drug (PF-06651600 or placebo).
| Age, Continuous(years) | PF-06651600 | Placebo | Total |
|---|---|---|---|
| Mean | 55.4 ± 11.72 | 54.2 ± 11.78 | 54.9 ± 11.67 |
| Sex: Female, Male(Participants) | PF-06651600 | Placebo | Total |
|---|---|---|---|
| Female | 33 | 24 | 57 |
| Male | 9 | 4 | 13 |
| Ethnicity (NIH/OMB)(Participants) | PF-06651600 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 41 | 26 | 67 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | PF-06651600 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 41 | 28 | 69 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2016 to primary completion in Dec 2017, 11 months.
Results were first posted in Dec 2018, 11 months after primary completion.
Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 11 months is below that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PF-06651600